Virpax Financial Statements From 2010 to 2026
| VRPX Stock | USD 0.01 0.00 0.00% |
Check Virpax Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virpax Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Virpax financial statements analysis is a perfect complement when working with Virpax Pharmaceuticals Valuation or Volatility modules.
Virpax |
Virpax Pharmaceuticals Company Return On Equity Analysis
Virpax Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Virpax Pharmaceuticals Return On Equity | -23.65 |
Most of Virpax Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Virpax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Virpax Pharmaceuticals has a Return On Equity of -23.6482. This indicator is about the same for the Biotechnology average (which is currently at -23.97) sector and 35.14% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Virpax Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Virpax Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Virpax Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Virpax Pharmaceuticals competition to find correlations between indicators driving Virpax Pharmaceuticals's intrinsic value. More Info.Virpax Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Virpax Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Virpax Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Virpax Pharmaceuticals Financial Statements
Virpax Pharmaceuticals investors use historical fundamental indicators, such as Virpax Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virpax Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Virpax Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Additional Tools for Virpax Pink Sheet Analysis
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.